Antioxidants may carry risk during breast cancer chemotherapy

Use of certain supplimnets like antioxidants may be risky during breast cancer chemotherapy. Cheap breast cancer chemotherapy drugs in India, economical breast cancer chemotherapy in India.

Share This Post

New studies have found that taking supplements like antioxidants may carry significant risk during breast cancer chemotherapy. A small study found out that patient taking supplements during breast cancer chemotherapy have higher chances of cancer recurrence leading to deaths. However, taking multivitamins is not found to be risky. The study was published online December 19, 2019 in the Journal of Clinical Oncology. It was led by researchers at the SWOG Cancer Research Network, funded by the National Cancer Institute.

Purpose of this study was to find out widespread use of dietary supplements during cancer treatment, few empirical data with regard to their safety or efficacy exist. Because of concerns that some supplements, particularly antioxidants, could reduce the cytotoxicity of chemotherapy, we conducted a prospective study ancillary to a therapeutic trial to evaluate associations between supplement use and breast cancer outcomes.

In the above-mentioned study 1134 patients who were undergoing chemotherapy in breast cancer were asked questions with respect to the supplement they are consuming. Questions were asked with respect to supplements like Vitamin A, C, E, carotenoids and Coenzyme Q10. It was found out that 41% of the patients are likely to have a recurrence and 40% of them are likely to die.

Co-author Christine B. Ambrosone, PhD, says cancer patients should be cautious about taking supplements while in chemotherapy. “People diagnosed with any cancer should talk with their doctors about whether they should be taking vitamins or other supplements,” she said in a statement. “I’d recommend that they try to get their vitamins and minerals – including antioxidants – from food. With a healthy and balanced diet, you can get all the nutrients your body needs, even while undergoing chemo.”

 

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Adagrasib with cetuximab has received accelerated approval by FDA for KRAS G12C-mutated colorectal cancer
Colon cancer

Adagrasib with cetuximab has received accelerated approval by FDA for KRAS G12C-mutated colorectal cancer

The FDA has granted accelerated approval to Adagrasib combined with Cetuximab for treating KRAS G12C-mutated colorectal cancer. This approval is based on promising clinical trial results showing enhanced efficacy of the drug duo. Adagrasib, a KRAS inhibitor, and Cetuximab, an EGFR inhibitor, together target the cancer more effectively, offering new hope for patients with this specific genetic mutation, aiming to improve survival rates and treatment outcomes.

Pembrolizumab with chemotherapy is approved by the USFDA for primary advanced or recurrent endometrial carcinoma
Endometrial cancer

Pembrolizumab with chemotherapy is approved by the USFDA for primary advanced or recurrent endometrial carcinoma

The USFDA has approved Pembrolizumab combined with chemotherapy for treating primary advanced or recurrent endometrial carcinoma. This approval is based on clinical trial data showing significant improvements in patient outcomes. Pembrolizumab, an immune checkpoint inhibitor, works by enhancing the body’s immune response against cancer cells. This combination therapy offers a new and promising treatment option for patients facing this challenging and often aggressive cancer.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy